@Article{096504018X15291727589740,
AUTHOR = {Yuma Nonomiya, Takashi Yokokawa, Kazuyoshi Kawakami, Kazuo Kobayashi, Takeshi Aoyama, 
Tomomi Takiguchi, Takahito Sugisaki, Kenichi Suzuki, Mitsukuni Suenaga, Takeru Wakatsuki, 
Kensei Yamaguchi, Yoshikazu Sugimoto, Toshihiro Hama},
TITLE = {Regorafenib-Induced Hand–Foot Skin Reaction Is More Severe  on the Feet Than on the Hands},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {5},
PAGES = {551--556},
URL = {http://www.techscience.com/or/v27n5/48570},
ISSN = {1555-3906},
ABSTRACT = {Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced 
hand–foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR 
was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data 
regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for 
regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the 
hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib.
We retrospectively examined the onset and severity of HFSR on the hands and feet of patients with metastatic 
colorectal cancer treated with regorafenib from May 2013 to October 2015 in the Cancer Institute Hospital of 
the Japanese Foundation for Cancer Research. In addition, we examined the possible association between preexisting clinical factors and severe HFSR. Our results showed that no significant difference in the incidence of 
HFSR of any grade was observed between the hands (71%) and feet (74%) (<i>p</i>=0.63). The incidence of grade 3 
HFSR was more frequent on the feet (33%) than on the hands (8%) (<i>p</i><0.01). The onset of grade 3 HFSR was 
earlier on the feet than on the hands (<i>p</i><0.001). No preexisting risk factor was identified. Our findings indicate 
that severe HFSR was more prevalent on the feet than on the hands, suggesting the need for appropriate screening for early detection and treatment of regorafenib-induced HSFR.},
DOI = {10.3727/096504018X15291727589740}
}